Comments
Granules India on Tuesday said the US health regulator had given its approval to the abbreviated new drug application filed by the drug firm for Loratadine tablets used to treat allergies.
“The US Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules India Ltd, for Loratadine tablets USP, 10 mg (OTC),” Granules India said in a filing to BSE.
The approved ANDA is bioequivalent to the Reference Listed Drug (RLD), Claritin tablets 10 mg by Bayer HealthCare LLC, the filing said.
The company further said that it intends to commercialise this product “shortly“.
The shares of Granules India were trading at Rs 127.70, up 0.47 per cent on BSE in the morning trade.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.